Literature DB >> 11970

Immediate hypersensitivity to tuberculin. In vivo and in vitro studies.

S M Tarlo, J H Day, P Mann, M P Day.   

Abstract

Immediate responses of hypersensitivity to skin testing with purified derivative of tuberculin (PPD) were observed in 2.3 percent of 3,248 patients seen in an allergy clinic, and the relationship to delayed responses was questioned. Immediate cutaneous reactions to testing with PPD appeared in all age groups and occurred in nonatopic patients but were more common in atopic patients (p less than 0.005). Delayed cutaneous reactions to testing with PPD occurred in only three out of 76 patients with immediate reactivity. Antihistaminic suppression of immediate reactivity was not followed by evidence of delayed cutaneous reactivity. In vitro tests of lymphocytic stimulation revealed indices of stimulation with PPD to be similar both in patients with immediate and delayed cutaneous reactivity. Failure to manifest delayed cutaneous reactivity following immediate cutaneous reactions alone may be explained by antigen-antibody binding and phagocytosis, by suppressor T-lymphocytes, or by impaired release or lack of response to T-lymphocytic mediators. Adverse reactions to administration of BCG vaccine in patients with immediate cutaneous reactivity might be anticipated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 11970     DOI: 10.1378/chest.71.1.33

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Risk Stratification With Coccidioidal Skin Test to Prevent Valley Fever Among Inmates, California, 2015.

Authors:  Charlotte Wheeler; Kimberley D Lucas; Gordana Derado; Orion McCotter; R Steven Tharratt; Tom Chiller; Janet C Mohle-Boetani
Journal:  J Correct Health Care       Date:  2018-08-13

2.  Cutaneous inflammation caused by inadvertent intradermal administration of DTP instead of PPD.

Authors:  D R Graham; B B Dan; P Bertagnoll; R E Dixon
Journal:  Am J Public Health       Date:  1981-09       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.